The LFB group

Created in 1994, LFB has been developing, manufacturing and marketing therapeutic proteins for patients with serious and often rare diseases.

Today, LFB is among the leading European bio-pharmaceutical companies providing mainly hospital-based healthcare professionals with plasma-derived or recombinant medicinal products in three major therapeutic areas: immunology, haemostasis, and intensive care.

As a French biopharmaceutical company, the LFB has initiated in 2018, a deep transformation plan, with a refocusing of its activities on its core business: to develop, to manufacture and to market medicines derived from plasma or recombinant proteins.

Several axes of strategic transformations have been implemented with the priority on industrial activities to support the growth of the LFB, the consolidation of its commercial leadership in France, and a strategic  international development.


LFB is a public company and is growing in a competitive sector. More than 2,500 employees of the LFB, both in France and worldwide, are totally committed to meeting the company mission.

Every year, LFB’s 15 biopharmaceuticals are used to treat hundreds of thousands of patients with serious and often rare diseases.